Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making waves in the industry with its innovative product pipeline and strong market performance.

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

The company expects its 2025 adjusted earnings to be in the range of $2.80 to $2.87 per share, above analysts' average ...

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its ... system and the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) devices were able to reduce ...

Sarasota Memorial Hospital has earned the #1 spot among the world's WATCHMAN providers protecting people with atrial ...

One of the standout products in Boston Scientific's portfolio is the Watchman FLX Left Atrial Appendage Closure (LAAC) device. Recent clinical trial results from the OPTION study demonstrated the ...

According to Boston Scientific, maker of the WATCHMAN device, Dr. Eckart has implanted more WATCHMAN devices than any other physician for the past two years. Approved by the FDA in 2015 ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Boston Scientific projected full-year revenue growth between 12.5% and 14.5%, compared with the prior year. The company's key growth drivers include its stroke prevention device, Watchman ...